EU Core Safety Profile
... No information is available about interaction between DOSTINEX and other ergot alkaloids; therefore, the concomitant use of these medications during long-term treatment with DOSTINEX is not recommended. Since DOSTINEX exerts its therapeutic effect by direct stimulation of dopamine receptors, it shou ...
... No information is available about interaction between DOSTINEX and other ergot alkaloids; therefore, the concomitant use of these medications during long-term treatment with DOSTINEX is not recommended. Since DOSTINEX exerts its therapeutic effect by direct stimulation of dopamine receptors, it shou ...
Adverse event - BioMed Central
... Adverse events were to be recorded regardless of whether they were thought to be associated with the study or the drug under investigation. An adverse event was considered to be related to use of a study drug if, in the opinion of the investigator, there was a reasonable possibility that the event m ...
... Adverse events were to be recorded regardless of whether they were thought to be associated with the study or the drug under investigation. An adverse event was considered to be related to use of a study drug if, in the opinion of the investigator, there was a reasonable possibility that the event m ...
Medication Mishaps in the Elderly Peron P, Marcum Z, Boyce R
... CAM use may have a negative impact on antihypertensive medication adherence It is essential to question patients about the use of non-prescription medications, since many do not self-report CAM use ...
... CAM use may have a negative impact on antihypertensive medication adherence It is essential to question patients about the use of non-prescription medications, since many do not self-report CAM use ...
06 Gout
... Most therapeutic strategies for gout involve lowering the uric acid level below the saturation point (<6 mg/dL), thus preventing the deposition of urate crystals. This can be accomplished by: 1.interfering with uric acid synthesis with allopurinol 2.increasing uric acid excretion with probenecid or ...
... Most therapeutic strategies for gout involve lowering the uric acid level below the saturation point (<6 mg/dL), thus preventing the deposition of urate crystals. This can be accomplished by: 1.interfering with uric acid synthesis with allopurinol 2.increasing uric acid excretion with probenecid or ...
New and alternative epilepsy treatments: Olgica Laban
... Limited duration of use No information on safety/interactions with other medications ...
... Limited duration of use No information on safety/interactions with other medications ...
Guidelines for prescribing of Ivabradine for symptomatic treatment of
... Ivabradine has a neutral effect on blood pressure. In general Ivabradine should not be prescribed with other drugs that suppress heart rate, including amiodarone, beta-blockers, diltiazem and sotalol. However it has been used safely in combination with beta blockade, so may be considered for use in ...
... Ivabradine has a neutral effect on blood pressure. In general Ivabradine should not be prescribed with other drugs that suppress heart rate, including amiodarone, beta-blockers, diltiazem and sotalol. However it has been used safely in combination with beta blockade, so may be considered for use in ...
Treatment injury case study
... incidence of BRONJ has yet to be established. Where bisphosphonates are used in high doses intravenously for the management of complications of malignancy, the risk of the development of BRONJ is in the range of 4-40%. An annual dose of IV zoledronate to manage postmenopausal osteoporosis does not c ...
... incidence of BRONJ has yet to be established. Where bisphosphonates are used in high doses intravenously for the management of complications of malignancy, the risk of the development of BRONJ is in the range of 4-40%. An annual dose of IV zoledronate to manage postmenopausal osteoporosis does not c ...
For patients with genotype 1b infection and CrCl below 30 mL/min
... •those infected with HBV but without detectable HBV DNA just prior to transplantation, we suggest a preemptive approach. This approach places an emphasis on minimizing drug exposure and the risk of drug resistance. We monitor serum HBV DNA every three months for the first year and every six months t ...
... •those infected with HBV but without detectable HBV DNA just prior to transplantation, we suggest a preemptive approach. This approach places an emphasis on minimizing drug exposure and the risk of drug resistance. We monitor serum HBV DNA every three months for the first year and every six months t ...
CSP Octreotide
... Long-term exposure to Sandostatin LAR of patients with acromegaly or gastroenteropancreatic tumours suggests that treatment with Sandostatin LAR does not increase the incidence of gallstone formation, compared with s.c. treatment. Ultrasonic examination of the gallbladder before and at about 6 month ...
... Long-term exposure to Sandostatin LAR of patients with acromegaly or gastroenteropancreatic tumours suggests that treatment with Sandostatin LAR does not increase the incidence of gallstone formation, compared with s.c. treatment. Ultrasonic examination of the gallbladder before and at about 6 month ...
EPVC Newsletter
... the Jaw (ONJ) and hypocalcaemia" with Denosumab to HCPs in Egypt. Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology. It is used for prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compressi ...
... the Jaw (ONJ) and hypocalcaemia" with Denosumab to HCPs in Egypt. Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology. It is used for prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compressi ...
ALLEGRON
... ideation. The patient should be informed that the response to alcohol may be exaggerated. Use in Pregnancy - Pregnancy Category C. Tricyclic antidepressants have not been shown to be associated with an increased incidence of birth defects. However, there is evidence of interference with central mono ...
... ideation. The patient should be informed that the response to alcohol may be exaggerated. Use in Pregnancy - Pregnancy Category C. Tricyclic antidepressants have not been shown to be associated with an increased incidence of birth defects. However, there is evidence of interference with central mono ...
Evaluation and Treatment of Hypertension
... Combining a thiazide with B blocker or an ACE has a synergistic effect, controlling BP in up to 85% Combination of ACEI with amlodipine may be superior to ACEI + diuretic in patients with diabetes (less CV events) Low doses of thiazide can be very effective in combination with ACE inhibitors (12.5 m ...
... Combining a thiazide with B blocker or an ACE has a synergistic effect, controlling BP in up to 85% Combination of ACEI with amlodipine may be superior to ACEI + diuretic in patients with diabetes (less CV events) Low doses of thiazide can be very effective in combination with ACE inhibitors (12.5 m ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... usually well aware of their associated adverse drug reactions (ADRs). The occurrence of these reactions is known to be frequent. The TB patient on treatment is taking more than one anti TB medication simultaneously and regimens last from many months to 2 years or more. This increases the likelihood ...
... usually well aware of their associated adverse drug reactions (ADRs). The occurrence of these reactions is known to be frequent. The TB patient on treatment is taking more than one anti TB medication simultaneously and regimens last from many months to 2 years or more. This increases the likelihood ...
Iraqi pharmacovigilance (center(IQPHVC
... Where suitable domperidone products are available for children, the recommended dose is 0.25 mg/kg bodyweight up to three times daily by mouth. In order to accurately measure doses to pediatric patients, oral suspensions should be given using an adapted graduated oral syringe. Domperidone products a ...
... Where suitable domperidone products are available for children, the recommended dose is 0.25 mg/kg bodyweight up to three times daily by mouth. In order to accurately measure doses to pediatric patients, oral suspensions should be given using an adapted graduated oral syringe. Domperidone products a ...
7 Intro to Antibiotic Therapy- A
... infections of the central nervous system (CNS) and the eye (treated with local instillation). ...
... infections of the central nervous system (CNS) and the eye (treated with local instillation). ...
Updated Synagis® Guidelines for RSV Prophylaxis
... The International Antiviral Society-USA (IAS-USA) published updated guidelines for the antiretroviral treatment (ART) of HIV infection in adults. Since early initiation of ART reduces the likelihood of HIV transmission while providing clinical benefit, IAS-USA advises to start ART as soon as possibl ...
... The International Antiviral Society-USA (IAS-USA) published updated guidelines for the antiretroviral treatment (ART) of HIV infection in adults. Since early initiation of ART reduces the likelihood of HIV transmission while providing clinical benefit, IAS-USA advises to start ART as soon as possibl ...
acetaminophen (paracetamol)
... Acetaminophen is analgesic and anti-pyretic drug, with some anti-inflammatory activity. Human toxicity Initial adverse effects of poisoning may be non-specific (nausea or vomiting) or absent. Clinical signs include e.g. hepatic necrosis, metabolic acidosis; renal tubular necrosis; myocardial damage; ...
... Acetaminophen is analgesic and anti-pyretic drug, with some anti-inflammatory activity. Human toxicity Initial adverse effects of poisoning may be non-specific (nausea or vomiting) or absent. Clinical signs include e.g. hepatic necrosis, metabolic acidosis; renal tubular necrosis; myocardial damage; ...
Mannitol Glass vial Product Sheet (PDF - 10 Ko)
... Risk of nauseas, vomiting, cephalgias, dizziness, tachycardia, thoracic pain, dehydration, blurred vision, hypotension or hypertension, mental confusion. Risk of extravasation with infiltration oedema. Less common cases of anaphylactoids reactions with urticaria. ...
... Risk of nauseas, vomiting, cephalgias, dizziness, tachycardia, thoracic pain, dehydration, blurred vision, hypotension or hypertension, mental confusion. Risk of extravasation with infiltration oedema. Less common cases of anaphylactoids reactions with urticaria. ...
Pandura Tablet Insert Size : L 4.25" x H 8.5"
... the target dose for most patients of 1 mg/day may be made after 3 days. Pediatric Patients: In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in t ...
... the target dose for most patients of 1 mg/day may be made after 3 days. Pediatric Patients: In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in t ...
Antifungal drugs
... lower levels of drug in the kidneys, reducing the incidence of nephrotoxicity. While less toxic, the lipid formulations are significantly more expensive than conventional amphotericin B. ...
... lower levels of drug in the kidneys, reducing the incidence of nephrotoxicity. While less toxic, the lipid formulations are significantly more expensive than conventional amphotericin B. ...
adverse reaction newsletter 1998:4
... lactic acidosis Nucleoside-analogue-associated hepatic steatosis and lactic acidosis have been known for some years. Other nucleoside analogues, namely zalcitabine and zidovudine, have also been reported. Recently, as a result of the analysis of the first post-marketing safety data on stavudine and ...
... lactic acidosis Nucleoside-analogue-associated hepatic steatosis and lactic acidosis have been known for some years. Other nucleoside analogues, namely zalcitabine and zidovudine, have also been reported. Recently, as a result of the analysis of the first post-marketing safety data on stavudine and ...
Slide 1
... Because the drug is pumped in, you have sustained concentrations in the perilymph even as the serum levels fall, so progression may occur after you stop taking the drug. You lose high frequency hearing first, may experience imbalance, vertigo, etc. These effects are cumulative. Risk factors include ...
... Because the drug is pumped in, you have sustained concentrations in the perilymph even as the serum levels fall, so progression may occur after you stop taking the drug. You lose high frequency hearing first, may experience imbalance, vertigo, etc. These effects are cumulative. Risk factors include ...
CHEMOTHERAPY OF AMOEBIASIS AND GIARDIASIS
... • It is converted into an active form by reduction of its nitro group, this binds to DNA and prevent nucleic acid formation; it is bacteriostatic. • Pharmacokinetics: metronidazole is well absorbed after oral or rectal administration and distributed to achieve sufficient concentration to eradicate i ...
... • It is converted into an active form by reduction of its nitro group, this binds to DNA and prevent nucleic acid formation; it is bacteriostatic. • Pharmacokinetics: metronidazole is well absorbed after oral or rectal administration and distributed to achieve sufficient concentration to eradicate i ...
Sulfanomides
... • After oral administration, most sulfa drugs are well absorbed except Sulfasalazine is not absorbed when administered orally or as a suppository. • Intravenous sulfonamides are generally reserved for patients who are unable to take oral preparations. • Because of the risk of sensitization, sulfa dr ...
... • After oral administration, most sulfa drugs are well absorbed except Sulfasalazine is not absorbed when administered orally or as a suppository. • Intravenous sulfonamides are generally reserved for patients who are unable to take oral preparations. • Because of the risk of sensitization, sulfa dr ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.